Podium Presentations


Podium Session I Monday 8 September 2008, 11:30AM-12:30PM
Research from China
CH1:	BURDEN OF DIABETES IN CHINA
	Jing L¹, Hu S² 1Novo Nordisk (China) Pharmaceuticals Co. Ltd, Beijing, China, ²Fudan University, Shanghai, China

CH2:	THE SMOKING EFFECTS ON THE ELDERLY IN CHINA
	Li L1, Chen Q¹, Jiang Y², Jia R³ ¹Peking University, Beijing, China, ²Peiking University, Beijing, China, ³Stockholm University, Stockholm, Sweden

CH3:	ECONOMIC BURDEN OF SMOKING IN CHINA
	Li L¹, Chen Q¹, Cui X¹, Yu J¹, Jia R² ¹Peking University, Beijing, China, ²Stockholm University, Stockholm, Sweden

CH4:	ECONOMIC EVALUATION OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER
	Chen W, Huang Y, Qiao N Fudan University, Shanghai, China

Research from India
IN1:	COST ANALYSIS OF TREATING ACUTE MYOCARDIAL INFARCTION IN INDIA
	Kochhar P¹, Suvarna V¹, Duttagupta S² ¹Pfizer India, Mumbai, India, ²Pfizer Inc, New York, NY, USA

IN2:	EVALUATION OF CURRENT TREATMENT PRACTICES AND OUTCOMES FOR PATIENTS WITH TYPE 2 DIABETES: PROFILE OF UNCONTROLLED DIABETES PATIENTS TREATED IN A PRIVATE CLINIC IN INDIA
	Morarka A, Davis S, Kochhar P, Suvarna V Pfizer India, Mumbai, India

IN3:	BURDEN OF NEUROPATHIC PAIN IN INDIAN PATIENTS ATTENDING URBAN, SPECIALTY CLINICS: RESULTS FROM A CROSS SECTIONAL STUDY
	Sule N; Kochhar P Pfizer India, Mumbai, Maharashtra, India

IN4:	AVAILABILITY AND PRICE OF TWO INHALATION MEDICINES FOR TREATMENT OF ASTHMA IN DIFFERENT STATES OF INDIA
	Kotwani A Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India

Research from Japan
JA1:	COST-UTILITY ANALYSIS OF SMOKING CESSATION THERAPY UNDER NATIONAL HEALTH INSURANCE SYSTEM IN JAPAN
	Igarashi A, Fukuda T, Tsutani K University of Tokyo, Bunkyo, Tokyo, Japan

JA2:	ASSESSING ITEMS ON THE SF-8 JAPANESE VERSION FOR THE HEALTH-RELATED QUALITY OF LIFE: A PSYCHOMETRIC ANALYSIS BASED ON THE NOMINAL CATEGORIES MODEL OF ITEM RESPONSE THEORY
	Tokuda Y¹, Okubo T², Ohde S¹, Jacobs J³, Takahashi O¹, Omata F³, Hinohara S¹, Fukui T¹ ¹St. Luke's Life Science Institute, Chuo, Tokyo, Japan, ²Japan Society for the Promotion of Science, Chiyoda City, Tokyo, Japan, ³St. Luke's Life Science Institute, Chuo City, Tokyo, Japan

JA3:	COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR IRON-DEFICIENCY ANEMIA IN MIDDLE-AGED WOMEN IN JAPAN
	Sakai M, Shimbo T, Takahashi Y Research Institute, International Medical Center of Japan, Shinjyuku-ku, Tokyo, Japan

JA4:	SAFETY OF OSELTAMIVIR (TAMIFLU®) AS MEASURED BY INCIDENCE OF INJURIES
	Okamoto E National Institute of Public Health, Wako-shi, Saitama, Japan

Research from South Korea
KO1:	COST-BENEFIT ANALYSIS OF UNIVERSAL ROTAVIRUS VACCINATION IN KOREA
	Sung Y Health Insurance Review and Assessment, Seoul, South Korea

KO2:	HEALTH-RELATED QUALITY OF LIFE OF COMMUNITY DWELLERS WITH MAJOR CHRONIC DISEASES
	Kang E Korea Institute for Health and Social Affairs, Seoul, South Korea

KO3:	HEALTH STATE UTILITY ASSESSMENT BY EQ5D IN CHRONIC HEPATITIS B PATIENTS IN KOREA
	Lee YR¹, Kwon SY², Lee YS³, Lee JH⁴, Choi HM¹, Lee CH² ¹GlaxoSmithKline, Seoul, South Korea, ²Konkuk University, Seoul, South Korea, ³Catholic University of Korea, Bucheon, South Korea, ⁴Sungkyunkwan University, Seoul, South Korea

KO4:	EVALUATION OF COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN KOREA
	Bae JY¹, Song HJ¹, Joe KH², Kim CH³, Song HR³, Ryu GC⁴, Kim DJ⁵, Lee EK¹ ¹Sook Myung Women's University, Seoul, South Korea, ²Department of Medicine, EulJi University, Seoul, South Korea, ³Family Medicine of Seoul Paik Hospital, Seoul, South Korea, ⁴Korea Institute for Health and Social Affairs, Seoul, South Korea, ⁵Catholic University of Korea, Holy Family Hospital, Seoul, South Korea

Research from Thailand
TH1:	BUDGET IMPACT ANALYSIS OF COMPULSORY LICENSING POLICY IMPLIMENTATION ON FOUR CANCER DRUGS IN THAILAND
	Mohara A, Praditsitthikorn N, Kingkaew P, Werayingyong P, Pattanaphesaj J, Yamabhai I, Teerawattananon Y Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

TH2:	ECONOMIC COSTS OF ALCOHOL ABUSE IN THAILAND: COST OF LAW ENFORCEMENT AND CRIMINAL JUSTICE
	Yothasamut J, Thavorncharoensap M, Teerawattananon Y, Lertpitakpong C, Thitiboonsuwan K Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

TH3:	COST-UTILITY ANALYSIS OF RECOMBINANT HUMAN ERYTHROPOIETIN IN CANCER PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY IN THAILAND
	Roungrong J¹, Teerawattananon Y¹, Chaikledkaew U² ¹Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, ²Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand

TH4:	COST-EFFECTIVENESS ANALYSIS OF SHIGELLA VACCINE FOR CHILDREN UNDER 5 YEARS OLD IN THAILAND
	Sribundit N¹, Riewpaiboon A², Chaikledkaew U², Noksakda N³ ¹Silpakorn University, Muang, Nakornpatom, Thailand, ²Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand, ³Udon Thani Province Health Office, Udon Thani, Udon Thani, Thailand

Podium Session II Tuesday 9 September 2008, 11:00AM-12:00PM
Cost-Effectiveness Studies
CE1:	COST-EFFECTIVENESS ANALYSES OF CHRONIC HEPATITIS B AND C MANAGEMENT IN TAIWAN – BASED ON REAL WORLD DATA FROM THE PILOT HEPATITIS REIMBURSEMENT PROGRAM
	Pwu RF¹, Chen CL², Kao JH², Lai MY² ¹Taipei Medical University, Taipei, Taiwan, ²National Taiwan University, Taipei, Taiwan

CE2:	A COST-EFFECTIVENESS ANALYSIS FOR CHRONIC HEPATITIS B VIRUS WITH CIRRHOSIS BY DISCRETE EVENT SIMULATION
	Luh H¹, Phua S² ¹National Chengchi University, Taipei, Taiwan, ²Agenix Limited, Singapore, Singapore

CE3:	COST-EFFECTIVENESS OF SMOKING CESSATION IN AUSTRALIA WITH VARENICLINE, A NOVEL PHARMACOTHERAPY.
	Brown A¹, Webb K², Kim H³, Liew D⁴ ¹Pfizer Australia Pty Limited, West Ryde, NSW, Australia, ²Pfizer Inc, Tadworth, Surrey, United Kingdom, ³Pfizer Inc, Sydney, NSW, Australia, ⁴University of Melbourne, Melbourne, Victoria, Australia

CE4:	THE LONG-TERM ECONOMIC IMPACT OF CERVICAL CANCER VACCINATION IN TAIWAN
	You SL¹, Tang CH², Ferko N³, Debicki D³, Chen YC⁴, Chen CJ¹ ¹Genomics Research Center, Academia Sinica, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³i3 Innovus Research Inc, Burlington, ON, Canada, ⁴GlaxoSmithKline, Taipei, Taiwan

Cost Studies
CS1:	COST ANALYSIS OF TREATING ACUTE MYOCARDIAL INFARCTION IN INDIA
	Lertpitakpong C1, Neramitpitagkul P¹, Thavorncharoensap M¹, Chaikledkaew U², Teerawattananon Y¹ ¹Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, ²Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand

CS2:	ANALYSIS OF SOCIOECONOMIC COST OF SMOKING IN KOREA
	Kim CH¹, Song HR², Park S³, Ko S⁴ ¹Department of Healthcare Policy and Management/Smoking Cessation Clinic of Seoul Paik Hospital, Seoul, South Korea, ²Inje University, Seoul, South Korea, ³Yonsei University, Seoul, South Korea, ⁴Pfizer Korea, Seoul, South Korea

CS3:	COST OF SUSPECTED INVASIVE PNEUMOCOCCAL DISEASES IN VIETNAMESE CHILDREN
	Riewpaiboon A¹, Anh DD², Tho LH³, Kim SA⁴, Kilgore PE⁴ ¹Faculty of Pharmacy Mahidol University, Ratchathevi, Bangkok, Thailand, ²National Institute of Hygiene and Epidemiology, Hanoi, Hanoi, Vietnam, ³Khanh Hoa Provincial Public Health Service, Nha Trang, Khanh Hoa, Vietnam, ⁴International Vaccine Institute, Kwanak, Seoul, South Korea

CS4:	THE IMPACT OF A HIGHER PD UTILIZATION RATE FOR DIALYSIS TREATMENT ON KOREA'S GOVERNMENT EXPENDITURES
	Chen L¹, Bang J², Walker D³ ¹Baxter Healthcare Asia Pacific, Shanghai, Shanghai, China, ²Baxter Healthcare Korea, Seoul, Seoul, South Korea, ³Baxter Healthcare US, Chicago, IL, USA

Health Policy
HP1:	THE IMPLICATIONS OF BENEFIT PACKAGE DESIGN: THE IMPACT ON POOR THAI HOUSEHOLDS OF EXCLUDING RENAL REPLACEMENT THERAPY
	IPrakongsai P¹, Tangcharoensathien V² ¹International Health Policy Program (IHPP), Nonthaburi, Nonthaburi, Thailand, ²International Health Policy Program - Thailand, Nonthaburi, Thailand

HP2:	SURVEY ON THE CURRENT HUMAN CAPACITY AND FUTURE NEEDS IN ECONOMIC EVALUATION IN THAILAND
	Chaikledkaew U¹, Lertpitakpong C², Orrawattanakul Y², Pimsawan N², Kulpeng W², Thavorncharoensap M², Teerawattananon Y², Tangcharoensathien V³ ¹Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand, ²Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, ³International Health Policy Program - Thailand, Nonthaburi, Thailand

HP3:	TREATMENT PATTERN AND OUTCOME ASSESSMENT OF ASTHMATIC PATIENTS ADMITTED TO ACCIDENT & EMERGENCY DEPARTMENT (ED) IN A TERTIARY TEACHING HOSPITAL
	Hussain SH¹, Wong SW¹, Ramli MN², Raja Mohamed AA² ¹University of Malaya, Kuala Lumpur, Federal Territory, Malaysia, ²University Malaya Medical Centre, Kuala Lumpur, Federal Territory, Malaysia

HP4:	A STUDY OF MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN SHANGHAI, CHINA
	Ye L1, Hu S2 ¹School of Public Health, Fudan University, Shanghai, China, ²Fudan University, Shanghai, China

Research on Methods
ME1:	A NEW APPROACH FOR MONITORING DRUG PRICE BEHAVIORS: MISCELLANEOUS ACQUISITION CAPABILITY (MAC)
	Udom-aksorn S¹, Sakulbumrungsil R² ¹Prince of Songkla University, Hatyai, Songkhla, Thailand, ²Chulalongkorn University, Patumwan, Bangkok, Thailand

ME2:	THE QUANTITY COST-EFFECTIVENESS ACCEPTABILITY CURVE BASED ON THE FULL INFORMATION OF INDIVIDUAL NET BENEFIT IN HEALTH-RELATED ECONOMIC EVALUATION
	Kim S, Suh J, Kim KH, Kim JS, Kim HK Novartis, Seoul, South Korea

ME3:	VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSE THEORY – APPLICATION OF KERNEL REGRESSION
	Lin HW¹, Pickard AS², Karabatsos G³, Mahady GB², Crawford SY², Popovich NG² ¹China Medical University, Taichung, Taiwan, ²College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, ³College of Education, University of Illinois at Chicago, Chicago, IL, USA

ME4:	FACTORS AFFECTING WILLINGNESS-TO-PAY FOR TREATMENT OF BLINDNESS IN THAI POPULATION
	Kulpeng W, Natanant S, Thavorncharoensap M, Teerawattananon Y Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

Patient-Reported Outcomes Studies
PR1:	HEALTH RELATED UTILITY OF AUSTRALIAN RHEUMATOID ARTHRITIS PATIENTS CORRELATES WITH HAQ BUT NOT TOTAL TENDER AND SWOLLEN JOINT COUNTS
	Norris S¹, Harvey C¹, Elliott L¹, Standfield L¹, Riordan J², Hall S³, Day R⁴, Nash P⁵, Thiru K⁶, Robertson J⁶, Palmer T⁶
	¹Health Technology Analysts Pty Ltd, Sydney, Australia, ²Illawara Rheumatology, Woollongong, Australia, ³Cabrini Medical Centre, Malvern, Australia, ⁴St Vincents Clinical Trial Centre, Sydney, Australia, ⁵Sixth Avenue Specialist Centre, Cotton Tree, Australia, ⁶Wyeth Australia, Sydney, Australia

PR2:	HEALTH RELATED QUALITY OF LIFE AND ITS ASSOCIATED FACTORS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA
	Jo MW¹, Lee WJ², Noh JH³, Song KH⁴, Choi YJ⁵
	¹Dongguk University, Gyeongju, Gyeongbuk, South Korea, ²Inje University Sanggye Paik Hospital, Seoul, South Korea, ³Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-Do, South Korea, ⁴Kunkuk University Hospital, Seoul, South Korea, ⁵Sanofi-Aventis Korea, Seoul, South Korea

PR3:	DOES COMBINING AMLODIPINE AND ATORVASTATIN INTO A SINGLE PILL IMPROVE ADHERENCE IN THE TARGET POPULATION? COMBINED EVIDENCE FROM TWO US RETROSPECTIVE DATABASE STUDIES
	Earle KL, Delahoy PJ, Dabin B, Brown AJ Pfizer Australia Pty Ltd, West Ryde, NSW, Australia

PR4:	DETERMINATION OF THE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OF THE 8-ITEM PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-8)
	Zhao YJ¹, Tan LC², Lau PN², Au WL², Li SC³, Luo N⁴
	¹National University of Singapore, Singapore, Singapore, Singapore, ²National Neuroscience Institute, Singapore, Singapore, ³University of Newcastle, Callaghan, NSW, Australia, ⁴National University of Singapore, Singapore, Singapore

Podium Session III Tuesday 9 September 2008, 2:45PM-3:45PM
Cancer
CN1:	THE IMPACT OF SUSPECTED SUPERFICIAL BLADDER CANCER ON HEALTHCARE RESOURCE UTILIZATION: A KOREAN PERSPECTIVE
	Barwell AC¹, Zyczynski T², Hong SJ³ ¹Abacus International, Bicester, Oxon, United Kingdom, ²GE Healthcare, Princeton, NJ, USA, ³Severance Hospital, Seoul, South Korea

CN2:	COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN
	Chao Y¹, Chang CS², Chen JS³, Chen LT⁴, Chung CH⁵, Hsieh RK⁶, Hwang WS⁷, Yang L⁸, De Reyder F⁹ ¹Taipei Veterans General Hospital, Taipei, Taiwan, ²Changhua Christian Memorial Hospital, Changhua, Taiwan, ³Chang Gung Memorial Hospital, LinKou, Taiwan, ⁴National Health Research Institutes, Taipei, Taiwan, ⁵Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, ⁶ Mackay Memorial Hospital, Taipei, Taiwan, ⁷Chi Mei Medical Center, Tainan, Taiwan, ⁸Roche Products Ltd, Taipei, Taiwan, ⁹F. Hoffmann-La Roche AG, Basel, Switzerland

CN3:	COST EFFECTIVENESS OF CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER
	Lim S¹, Lim G², Goh A³ ¹Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, ²Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, ³ClinResearch Sdn Bhd, Kuala Lumpur, Malaysia

CN4:	IMATINIB IS COST-EFFECTIVE THAN INTERFERON-ALPHA (IFN) FOR PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA FROM THE CHINESE PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
	Wang C¹, Chen Z², Feng W³ ¹Shanghai Jiaotong University Affiliated First Hospital, Shanghai, Shanghai, China, ²Shanghai Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China, ³Novartis Pharmaceuticals, Florham Park, NJ, USA

Cardiovascular Disease
CV1:	TO COMPARE THE THERMAL RESPONSE OF NIFEDIPINE WITH GINKGO IN PATIENTS WITH RAYNAUD'S DISEASE BY DIGITAL INFRARED THERMOGRAPHIC IMAGING ; KOREAN RAYNAUD DITI STUDY
	Choi WS¹, Kim SH¹, Ju SY¹, Chung JH¹, Lee JB², Kim CM¹ ¹Catholic University, Seoul, South Korea, ²Korea University, Ansan, South Korea

CV2:	A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF STATINS ON REDUCING ACUTE CORONARY SYNDROME AND STROKE EVENTS
	Tamteeranon Y¹, Chaikledkaew U¹, Khonputsa P², Teerawattananon Y¹ ¹Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, ²Setting Priority using Information on Cost-Effectiveness (SPICE), Nonthaburi, Thailand

CV3:	UTILIZATION OF NEW DRUG AND MEDICAL EXPENDITURE OF HYPERTENSION PATIENTS: EMPIRICAL EVIDENCE FROM ANGIOTENSIN II RECEPTOR BLOCKERS IN TAIWAN
	Liu YM, Kao Yang YH, Chang CY ¹National Cheng Kung University, Tainan, Taiwan

CV4:	THE CLINICAL AND ECONOMIC BENEFIT OF CHANGING THE NATIONAL REIMBURSEMENT CRITERIA FOR CHOLESTEROL LOWERING DRUG THERAPY IN KOREA
	Kang HY¹, Liew D², Ko S³, Kim J⁴ ¹Yonsei University, Seoul, South Korea, ²University of Melbourne, Melbourne, Victoria, Australia, ³Pfizer Korea, Seoul, South Korea, ⁴Konyang University, Chungnam, South Korea

Diabetes
DB1:	RISK FACTORS FOR AND INCIDENCE RATE OF TYPE 2 DIABETES RELATED HOSPITALIZATION USING CLAIMS DATA IN SOUTH KOREA
	Kim CM¹, Choi IS², Jang SM³, Gerth W⁴, Suh DC², Choi WS¹ ¹Catholic University, Seoul, Suhcho-gu, South Korea, ²Rutgers University, Piscataway, NJ, USA, ³Health Insurance Review Agency, Seoul, South Korea, ⁴Merck & Co., Inc, Whitehouse Station, NJ, USA

DB2:	A SURVEY OF DIABETES KNOWLEDGE AMONG THE GENERAL POPULATION IN THAILAND
	Pongmesa T¹, Wee HL¹, Li SC² ¹National University of Singapore, Singapore, Singapore, ²University of Newcastle, Callaghan, NSW, Australia

DB3:	ACARBOSE IN ADDITION TO EXISTING TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES: HEALTH ECONOMIC ANALYSES IN A CHINESE SETTING
	Chen X¹, Clegg JP², Chen L¹, Yu H³, Wittrup-Jensen KU⁴, Valentine WJ² ¹Fu Dan University, Shanghai, China, ²IMS Health, Basel, Switzerland, ³Bayer Healthcare Co. Ltd, Shanghai, China, ⁴Bayer Schering Pharma AG, Berlin, Germany

DB4:	MODELLING THE COST-EFFECTIVENESS OF ACARBOSE IN PREVENTING TYPE 2 DIABETES IN A SOUTH KOREAN SETTING
	JongMann K¹, Clegg JP², Chang K¹, JuYeol P¹, Wittrup-Jensen KU³, Palmer AJ⁴, Roze S⁴, Valentine WJ⁵ ¹Bayer, Seoul, South Korea, ²IMS, Allschwil, Switzerland, ³Bayer Schering Pharma AG, Berlin, Germany, ⁴CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, ⁵IMS Health, Basel, Switzerland

Infection
IF1:	EFFECTIVENESS AND SAFETY OF COMBINATION THERAPY OF ZIDOVUDINE AND LAMIVUDINE FOR PREVENTING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV: A SYSTEMATIC REVIEW
	Wang L¹, Li Y², Sun X², Peng L¹ ¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

IF2:	AN ECONOMIC EVALUATION OF ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS IN KOREA
	Jo C1, Kim SI2, Jun S³ ¹Hallym University, Chuncheon, South Korea, ²Catholic University, Seoul, South Korea, 3Korea Institute of Environment and Health, Seoul, South Korea

IF3:	THE QUALITY OF SYSTEMATIC REVIEWS OR META-ANALYSES ON PERINATAL ANTIRETROVIRAL THERAPIES FOR PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV
	Wang L¹, Peng L¹, Sun X², Li Y² ¹Sichuan University, Chengdu, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, China

IF4:	A HEALTH ECONOMICS MODEL TO ESTIMATE THE COST DIFFERENCE BETWEEN STOCKPILING VERSUS NOT STOCKPILING PRE-PANDEMIC INFLUENZA VACCINE
	Tucker D¹, Williams P², Standaert BA³
	¹GlaxoSmithKline Biologicals, Wavre, Belgium, ²Navitas BioPharma Consulting, Buckinghamshire, United Kingdom, ³GlaxoSmithKline Biologicals, Rixensart, Belgium

Mental Health
MH1:	PATIENT AND PHYSICIAN SATISFACTION WITH RISPERIDONE LONG-ACTING INJECTION: INTERIM RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA
	Lee MS¹, Kim YS², Lee DG³, Paik IH⁴, Lee HK⁴, Jung IK¹, Lee JG⁵, Hah TM⁶, Zhao Z⁷ ¹Korea University, Seoul, South Korea, ²Seoul National University, Seoul, South Korea, ³Goyang Mental Hospital, Goyang, South Korea, ⁴The Catholic University of Korea, Seoul, South Korea, ⁵Masan Dongsuh Hospital, Masan, South Korea, ⁶Busan Dongrae Hospital, Busan, South Korea, ⁷JJPS, Raritan, NJ, USA

MH2:	HOSPITALIZATION ASSOCIATED WITH RISPERIDONE LONG ACTING INJECTION TREATMENT IN SCHIZOPHRENIA: 6-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA
	Kim YS¹, Lee MS², Lee DG³, Paik IH⁴, Lee HK⁴, Jung IK², Lee JG⁵, Hah TM⁶, Zhao Z⁷ ¹Seoul National University, Seoul, South Korea, ²Korea University, Seoul, South Korea, ³Goyang Mental Hospital, Goyang, South Korea, ⁴The Catholic University of Korea, Seoul, South Korea, ⁵Masan Dongsuh Hospital, Masan, South Korea, ⁶Busan Dongrae Hospital, Busan, South Korea, ⁷JJPS, Raritan, NJ, USA

MH3:	ECONOMIC EVALUATION OF PALIPERIDONE ER IN THE TREATMENT OF SCHIZOPHRENIA PATIENTS IN TAIWAN
	Yang YK¹, Liu CY², Pwu RF³, Ko SY⁴, Tsai IC⁴ ¹National Cheng Kung University, Tainan, Taiwan, ²Chang Gung Memorial Hospital, Tao Yuan, Taiwan, ³Taipei Medical University, Taipei, Taiwan, ⁴Janssen Cilag Taiwan, Taipei, Taiwan

MF4:	RISPERIDONE LONG ACTING INJECTION TREATMENT IN SCHIZOPHRENIA: 6-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA
	Lee MS¹, Kim YS², Lee DG³, Paik IH⁴, Lee HK⁴, Jung IK¹, Lee JG⁵, Hah TM⁶, Zhao Z⁷ ¹Korea University, Seoul, South Korea, ²Seoul National University, Seoul, South Korea, 3Goyang Mental Hospital, Goyang, South Korea, ⁴The Catholic University of Korea, Seoul, South Korea, ⁵Masan Dongsuh Hospital, Masan, South Korea, ⁶Busan Dongrae Hospital, Busan, South Korea, ⁷JJPS, Raritan, NJ, USA